These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38934347)

  • 41. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.
    Banister SD; Connor M
    Handb Exp Pharmacol; 2018; 252():165-190. PubMed ID: 29980914
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical and financial implications of emergency department visits for synthetic marijuana.
    Rowley E; Benson D; Tiffee A; Hockensmith A; Zeng H; Jones GN; Musso MW
    Am J Emerg Med; 2017 Oct; 35(10):1506-1509. PubMed ID: 28457767
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid Receptor Agonists: From Horizon Scanning to Notification.
    Hill SL; Dunn M; Cano C; Harnor SJ; Hardcastle IR; Grundlingh J; Dargan PI; Wood DM; Tucker S; Bartram T; Thomas SHL
    Clin Chem; 2018 Feb; 64(2):346-354. PubMed ID: 29038156
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rhabdomyolysis related to acute recreational drug toxicity-A Euro-DEN study.
    Waldman W; Kabata PM; Dines AM; Wood DM; Yates C; Heyerdahl F; Hovda KE; Giraudon I; ; Dargan PI; Sein Anand J
    PLoS One; 2021; 16(3):e0246297. PubMed ID: 33705425
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acute health problems due to recreational drug use in patients presenting to an urban emergency department in Switzerland.
    Liakoni E; Dolder PC; Rentsch K; Liechti ME
    Swiss Med Wkly; 2015; 145():w14166. PubMed ID: 26218967
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epidemiology, clinical features and management of patients presenting to European emergency departments with acute cocaine toxicity: comparison between powder cocaine and crack cocaine cases.
    Miró Ò; Dargan PI; Wood DM; Dines AM; Yates C; Heyerdahl F; Hovda KE; Giraudon I; ; Galicia M
    Clin Toxicol (Phila); 2019 Aug; 57(8):718-726. PubMed ID: 30696283
    [No Abstract]   [Full Text] [Related]  

  • 47. Synthetic Cannabinoid-Related Deaths in England, 2012-2019.
    Yoganathan P; Claridge H; Chester L; Englund A; Kalk NJ; Copeland CS
    Cannabis Cannabinoid Res; 2022 Aug; 7(4):516-525. PubMed ID: 33998886
    [No Abstract]   [Full Text] [Related]  

  • 48. Spicing it up - synthetic cannabinoid receptor agonists and psychosis - a systematic review.
    Hobbs M; Kalk NJ; Morrison PD; Stone JM
    Eur Neuropsychopharmacol; 2018 Dec; 28(12):1289-1304. PubMed ID: 30454908
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthetic cannabinoid receptor agonists: classification and nomenclature.
    Potts AJ; Cano C; Thomas SHL; Hill SL
    Clin Toxicol (Phila); 2020 Feb; 58(2):82-98. PubMed ID: 31524007
    [No Abstract]   [Full Text] [Related]  

  • 50. Reported exposures to derived cannabis products in California before and after the 2018 federal reclassification of hemp.
    Madan K; Schmidt S; Chami RF; Ho R; Lewis JC; Apollonio DE
    Int J Drug Policy; 2024 Feb; 124():104313. PubMed ID: 38194724
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Co-exposure to gamma-hydroxybutyrate is associated with attenuated neuropsychiatric and stimulant effects of metamfetamine.
    Greene SL; Syrjanen R; Hodgson SE; Abouchedid R; Schumann J
    Clin Toxicol (Phila); 2024 May; 62(5):303-313. PubMed ID: 38884342
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
    van Amsterdam J; Brunt T; van den Brink W
    J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Narrative Review of the Pharmacodynamics, Pharmacokinetics, and Toxicities of Illicit Synthetic Cannabinoid Receptor Agonists.
    Lea Houston M; Morgan J; Kelso C
    Mini Rev Med Chem; 2024; 24(1):92-109. PubMed ID: 37190813
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Synthetic Cannabinoid Receptor Agonist-Associated Psychotic Disorder: A Case Report].
    Sönmez İ; Köşger F
    Turk Psikiyatri Derg; 2016; 27(1):63-6. PubMed ID: 27369687
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: Are synthetic cannabinoids actually preferred to other drugs?
    Smith KE; Staton M
    Subst Abus; 2019; 40(2):160-169. PubMed ID: 30457960
    [No Abstract]   [Full Text] [Related]  

  • 56. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201.
    McQuade D; Hudson S; Dargan PI; Wood DM
    Eur J Clin Pharmacol; 2013 Mar; 69(3):373-6. PubMed ID: 22936123
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB
    Grafinger KE; Cannaert A; Ametovski A; Sparkes E; Cairns E; Banister SD; Auwärter V; Stove CP
    Drug Test Anal; 2021 Jul; 13(7):1402-1411. PubMed ID: 33769699
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.
    Chung EY; Cha HJ; Min HK; Yun J
    Arch Pharm Res; 2021 Apr; 44(4):402-413. PubMed ID: 33811300
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Change in the new psychoactive substances associated with Emergency Department acute toxicity presentations associated with the introduction of the UK 2016 Psychoactive Substances Act.
    Webb NE; Wood DM; Greene SL; Hunter LJ; Archer JRH; Dines AM; Dargan PI
    Clin Toxicol (Phila); 2019 Jan; 57(1):36-41. PubMed ID: 30067112
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Involuntary MDMB-4en-PINACA intoxications following cannabis consumption: clinical and analytical findings.
    Goncalves R; Labadie M; Chouraqui S; Peyré A; Castaing N; Daveluy A; Molimard M
    Clin Toxicol (Phila); 2022 Apr; 60(4):458-463. PubMed ID: 34850659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.